Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma-Reference-Cited by-同舟云学术

Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma

Published:2019 Issue:47 Volume:11 Page:5976-5983
ISSN:1759-9660
Container-title:Analytical Methods
language:en
Short-container-title:Anal. Methods

Author:

Vay Manuela¹²³⁴^ORCID,Skopp Gisela⁵²⁶⁴⁷^ORCID,Mikus Gerd¹²³⁴^ORCID,Burhenne Jürgen¹²³⁴^ORCID

Affiliation:

1. Department of Clinical Pharmacology and Pharmacoepidemiology

2. Heidelberg University Hospital

3. 69120 Heidelberg

4. Germany

5. Institute of Legal and Traffic Medicine

6. 69115 Heidelberg

7. Forensic Toxicological Centre GmbH

Abstract

We developed and validated a human plasma LC-MS/MS assay according to FDA guidelines to determine the impact of the CYP2D6 inhibitor paroxetine on the pharmacokinetics of the assumed specific CYP2D6 substrate yohimbine.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Chemical Engineering,Analytical Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/AY/C9AY01715A

Reference25 articles.

1. Yohimbine: a clinical review

2. Pharmacological prospects for α2-adrenoceptor antagonist therapy

3. Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum

4. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA

5. The pharmacokinetics of yohimbine in man

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial;Clinical Pharmacokinetics;2020-02-15